http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-055751-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fda45c540f11df3a7fe71d54a70562a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| filingDate | 2006-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2007-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-055751-A1 |
| titleOfInvention | THIOPHEN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS |
| abstract | Pharmaceutical compositions and their use as immunosuppressants. Claim 1: A compound selected from the group consisting of thiophenes of the formula (1), wherein: ring A represents a group of formulas (2) or (3); R1 represents hydrogen, C1-5 alkyl, C1-5 alkoxy, or halogen; R2 represents hydrogen, C1-5 alkyl, C1-5 alkoxy, trifluoromethyl, trifluoromethoxy, or halogen; R3 represents hydrogen, hydroxyC1-5 alkyl, 2,3-dihydroxypropyl, di- (hydroxyC1-5 alkyl) -C1-5 alkyl, -CH2- (CH2) k-NR31R32, (azetidin-3-carboxylic acid) -1-yl-methyl, (C1-5 alkyl ester of azetidin-3-carboxylic acid) -1-yl-methyl, 2 [(azetidin-3-carboxylic acid) -1-yl] -ethyl, 2 - [(alkyl C1-5 azetidin-3-carboxylic acid) -1-yl] -ethyl, 3- [(azetidin-3-carboxylic acid) -1-yl] -propyl, 3 - [(C1-5 alkyl ester of azetidin acid -3-carboxylic) -1-yl] -propyl, (pyrrolidin-3-carboxylic acid) -1-yl-methyl, (C1-5 alkyl ester of pyrrolidin-3-carboxylic acid) -1-yl-methyl, (pyrrolidin-2-carboxylic acid) -1-yl-methyl, (C1-5 alkyl ester of pyrrolidin-2-carboxylic acid) -1-yl-methyl, 2 - [(pyrrolidin-3-carboxylic acid) -1- il] -ethyl, 2 - [(C1-5 alkyl ester of pyrrolidin-3-carboxylic acid) -1-yl] -ethyl, 2 - [(pyrrolidin-2-carboxylic acid) -1-yl] -ethyl, 2 - [(C1-5 alkyl ester of pyrrolidin-2-carboxylic acid) -1-yl] -ethyl, 3 - [(pyrro acid lidin-3-carboxylic) -1-yl] -propyl, 3 - [(C1-5 alkyl ester of pyrrolidin-3-carboxylic acid) -1-yl] -propyl, 3 - [(pyrrolidin-2-carboxylic acid) -1-yl] -propyl, 3 - [(C1-5 alkyl pyrrolidin-2-carboxylic acid ester) -1-yl] -propyl, --CH2- (CH2) n-COOH, -CH2- (CH2) n-CONR31R32, -CO-NHR31, - (CH2) nCH (OH) -CH2-NR31R32, hydroxy, C1-5 alkoxy, fluoroC1-5 alkoxy, hydroxyC2-5 alkoxy, di- (hydroxyC1-5 alkyl) -C1-5 alkoxy, 1-glyceryl, 2-glyceryl, 2-hydroxy-3-methoxy-propoxy, -OCH2- (CH2) m-R31R32, 2-pyrrolidin-1-yl-ethoxy, 3-pyrrolidin-1-yl -propoxy, 2-piperazin-1-yl-ethoxy, 2- [4- (C1-5 alkyl) -piperazin-1-yl] -ethoxy, 2- [4- (2-hydroxy-ethyl) -piperazin-1- il] -ethoxy, 3-piperazin-1-yl-propoxy, 3- [4- (C1-5 alkyl) -piperazin-1-yl] -propoxy, 3- [4- (2-hydroxy-ethyl) -piperazin- 1-yl] -propoxy, 2-morpholin-4-yl-ethoxy, 3-morpholin-4-yl-propoxy, 2 - [(azetidin-3-carboxylic acid) -1-yl] -ethoxy, 2 - [( C1-5 alkyl azetidin-3-carboxylic acid) -1-yl] -ethoxy, 2 - [(pyrrolidin-3-carboxylic acid) -1-yl] -ethoxy, 2 - [(C1-5 alkyl ester of pyrrolidin-3-carboxylic acid) -1-yl] -ethoxy, 2 - [(pyrrolidin-2-carboxylic acid) -1-yl] -ethoxy, 2 - [(C1 alkyl -5 pyrrolidin-2-carboxylic acid) -1-yl] -ethoxy, 2 - [(2-hydroxy-pyrrolidin) -1-yl] -ethoxy, 2 - [(3-hydroxy-pyrrolidin) -1- il] -ethoxy, 3 - [(azetidin-2-carboxylic acid) -1-yl] -propoxy, 3 - [(C1-5 alkyl ester of azetidin-3-carboxylic acid) -1-yl] -propoxy, 3 - [(pyrrolidin-3-carboxylic acid) -1-yl] -propoxy, 3 - [(C1-5 alkyl ester of pyrrolidin-3-carboxylic acid) -1-yl] -propoxy, 3 - [(pyrrolidin- 2-carboxylic) -1-yl] -propoxy, 3 - [(C1-5 alkyl pyrrolidin-2-carboxylic acid ester) -1-yl] -propoxy, 3- [(2-hydroxy-pyrrolidin) -1- il] -propoxy, 3 - [(3-hydroxy-pyrrolidin) -1-yl] -propoxy, 2-amino-3-hydroxy-2-hydroxymethyl-propoxy, -O-CH2-CONR31R32, 3-carbamoyl-propoxy, 3- (C1-5 alkylcarbamoyl) propoxy, 3- (2-hydroxyethylcarbamoyl) propoxy, -OCH2-CH (OH) -CH2- NR31R32, 3 - [(azetidin-3-carboxylic acid) -1-yl] -2 -hydroxypropoxy, 3 - [(C1-5 alkyl) er of azetidin-3-carboxylic acid) -1-yl] -2-hydroxypropoxy, 2-hydroxy-3 - [(pyrrolidin-3-carboxylic acid) -1-yl] -propoxy, 2-hydroxy-3 - [( C1-5 alkyl pyrrolidin-3-carboxylic acid) -1-yl] -propoxy, 2-hydroxy-3 - [(pyrrolidin-2-carboxylic acid) -1-yl] -propoxy, 2-hydroxy-3- [ (C1-5 alkyl pyrrolidin-2-carboxylic acid ester) -1-yl] -propoxy, 2-hydroxy-3 - [(2-hydroxy-pyrrolidin) -1-yl] -propoxy, 2-hydroxy-3- [(3-hydroxy-pyrrolidin) -1-yl] -propoxy, 2-hydroxy-3-pyrrolidin-1-yl-propoxy, 2-hydroxy-3-piperazin-1-yl-propoxy, 2-hydroxy-3- [4- (C1-5 alkyl) -piperazin-1-yl] -propoxy, 2-hydroxy-3- [4- (2-hydroxy-ethyl) -piperazin-1-yl] -propoxy, 2-hydroxy-3 -morpholin-4-yl-propoxy, -NR31R32, -NHCO-R31, -CH2- (CH2) k-NHSO2R33, - (CH2) nCH (OH) -CH2-NHSO2R33, -OCH2- (CH2) m-NHSO2R33, -OCH2-CH (OH) -CH2-NHSO2R33, -CH2- (CH2) k-NHCOR34, - (CH2) nCH (OH) -CH2-NHCOR34, -OCH2- (CH2) m-NHCOR34, or -OCH2-CH (OH) -CH2-NHCOR34; R31 represents hydrogen, methyl, ethyl, 1-propyl, 2-propyl, 2-hydroxyethyl, 2-hydroxy-1-hydroxymethyl-ethyl, 2-C 1-5 alkoxyethyl, 3-hydroxypropyl, 3-C 1-5 alkoxypropyl, 2-aminoethyl, 2- (C1-5 alkylamino) ethyl, 2- (di- (C1-5 alkyl) amino) ethyl, carboxymethyl, C1-5 alkylcarboxymethyl, 2-carboxy ethyl, or 2- (C1-5 alkylcarboxy) ethyl; R32 represents hydrogen, methyl, or ethyl; R33 represents methyl, ethyl, propyl, isopropyl, butyl, 2-hydroxyethyl, 2-methoxyethyl, methylamino, ethylamino, propylamino, isopropylamino, n-butylamino, or dimethylamino; R34 represents hydroxymethyl, hydroxyethyl, aminomethyl, methylaminomethyl, dimethylaminomethyl, aminoethyl, 2-methylamino-ethyl, or 2-dimethylamino-ethyl; k represents the integer 1, 2, or 3; m represents the whole number 1 or 2; n represents 0, 1, or 2; and R4 represents hydrogen, C1-5 alkyl, or halogen; and the configuration isomers such as optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, and mixtures of diastereomeric racemates, as well as salts and solvent complexes of said compounds, and morphological forms. |
| priorityDate | 2005-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 69.